
Francisca Gonzalez-Rubio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/449567/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identifying multimorbidity profiles associated with COVID-19 severity in chronic patients using network analysis in the PRECOVID Study. Scientific Reports, 2022, 12, 2831.	1.6	10
2	Multimorbidity Profiles and Infection Severity in COVID-19 Population Using Network Analysis in the Andalusian Health Population Database. International Journal of Environmental Research and Public Health, 2022, 19, 3808.	1.2	4
3	How to Improve Healthcare for Patients with Multimorbidity and Polypharmacy in Primary Care: A Pragmatic Cluster-Randomized Clinical Trial of the MULTIPAP Intervention. Journal of Personalized Medicine, 2022, 12, 752.	1.1	5
4	Effectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial. Trials, 2022, 23, .	0.7	2
5	Influenza Vaccination: An Ally to Mitigate Influenza-associated Risks During the Coronavirus Disease 2019 (COVID-19) Pandemic. Clinical Infectious Diseases, 2021, 72, 2249-2250.	2.9	4
6	Multimorbidity clusters in patients with chronic obstructive airway diseases in the EpiChron Cohort. Scientific Reports, 2021, 11, 4784.	1.6	17
7	Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data. International Journal of Environmental Research and Public Health, 2021, 18, 4754.	1.2	12
8	Changes in Multimorbidity and Polypharmacy Patterns in Young and Adult Population over a 4-Year Period: A 2011–2015 Comparison Using Real-World Data. International Journal of Environmental Research and Public Health, 2021, 18, 4422.	1.2	5
9	Analytical errors due to biotin interference. Medicina ClÃnica, 2021, 157, 95-96.	0.3	0
10	Baseline Drug Treatments as Indicators of Increased Risk of COVID-19 Mortality in Spain and Italy. International Journal of Environmental Research and Public Health, 2021, 18, 11786.	1.2	6
11	Chronic diseases associated with increased likelihood of hospitalization and mortality in 68,913 COVID-19 confirmed cases in Spain: A population-based cohort study. PLoS ONE, 2021, 16, e0259822.	1.1	31
12	Evolution of polypharmacy in a spanish population (2005â€⊋015): A database study. Pharmacoepidemiology and Drug Safety, 2020, 29, 433-443.	0.9	38
13	Training primary care professionals in multimorbidity management: Educational assessment of the eMULTIPAP course. Mechanisms of Ageing and Development, 2020, 192, 111354.	2.2	8
14	Baseline Chronic Comorbidity and Mortality in Laboratory-Confirmed COVID-19 Cases: Results from the PRECOVID Study in Spain. International Journal of Environmental Research and Public Health, 2020, 17, 5171.	1.2	83
15	Initial Therapy, Regimen Change, and Persistence in a Spanish Cohort of Newly Treated Type 2 Diabetes Patients: A Retrospective, Observational Study Using Real-World Data. International Journal of Environmental Research and Public Health, 2020, 17, 3742.	1.2	7
16	Do Centenarians Die Healthier than Younger Elders? A Comparative Epidemiological Study in Spain. Journal of Clinical Medicine, 2020, 9, 1563.	1.0	15
17	Multimorbidity Patterns in the General Population: Results from the EpiChron Cohort Study. International Journal of Environmental Research and Public Health, 2020, 17, 4242.	1.2	37
18	Adherence to treatment of hypertension, hypercholesterolaemia and diabetes in an elderly population of a Spanish cohort. Medicina ClÃnica (English Edition), 2019, 153, 1-5.	0.1	12

#	Article	IF	CITATIONS
19	Treatment Patterns of Diabetes in Italy: A Population-Based Study. Frontiers in Pharmacology, 2019, 10, 870.	1.6	23
20	Health of Spanish centenarians: a cross-sectional study based on electronic health records. BMC Geriatrics, 2019, 19, 226.	1.1	9
21	Patterns of multimorbidity and polypharmacy in young and adult population: Systematic associations among chronic diseases and drugs using factor analysis. PLoS ONE, 2019, 14, e0210701.	1.1	41
22	Adherencia al tratamiento de hipertensión arterial, hipercolesterolemia y diabetes en población anciana de una cohorte española. Medicina ClÃnica, 2019, 153, 1-5.	0.3	11
23	Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study. International Journal of Epidemiology, 2018, 47, 382-384f.	0.9	61
24	Adherence to chronic medication in older populations: application of a common protocol among three European cohorts. Patient Preference and Adherence, 2018, Volume 12, 1975-1987.	0.8	68
25	Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety, 2018, 27, 953-961.	0.9	2
26	Shock anafiláctico por omeprazol. GastroenterologÃa Y HepatologÃa, 2017, 40, 20-21.	0.2	4
27	Melanosis coli asociada a diacereÃna. GastroenterologÃa Y HepatologÃa, 2017, 40, 93-95.	0.2	3
28	Anaphylactic shock due to omeprazole. GastroenterologÃa Y HepatologÃa (English Edition), 2017, 40, 20-21.	0.0	0
29	Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany. Pharmacoepidemiology and Drug Safety, 2017, 26, 615-624.	0.9	14
30	Correlation between adenoma detection rate in colonoscopy―and fecal immunochemical testingâ€based colorectal cancer screening programs. United European Gastroenterology Journal, 2017, 5, 255-260.	1.6	46
31	Hipovitaminosis D: buscando la evidencia. Endocrinologia, Diabetes Y NutriciÓn, 2017, 64, 512-513.	0.1	1
32	Effectiveness of an intervention for improving drug prescription in primary care patients with multimorbidity and polypharmacy: study protocol of a cluster randomized clinical trial (Multi-PAP) Tj ETQq0 0 0	rgB I. ‡Over	loc\$#10 Tf 50
33	Multimorbidity and weight loss in obese primary care patients: longitudinal study based on electronic healthcare records. BMJ Open, 2015, 5, e006227-e006227.	0.8	7
34	Global health care use by patients with type-2 diabetes: Does the type of comorbidity matter?. European Journal of Internal Medicine, 2015, 26, 203-210.	1.0	30
35	Association between physical activity, multimorbidity, self-rated health and functional limitation in the Spanish population. BMC Public Health, 2014, 14, 1170.	1.2	64
36	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. Clinical Gastroenterology and Hepatology, 2014, 12, 1708-1716.e4.	2.4	13

#	Article	IF	CITATIONS
37	Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointestinal Endoscopy, 2013, 78, 333-341.e1.	0.5	62
38	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. Journal of the National Cancer Institute, 2013, 105, 878-886.	3.0	25
39	Polypharmacy Patterns: Unravelling Systematic Associations between Prescribed Medications. PLoS ONE, 2013, 8, e84967.	1.1	54
40	Multimorbidity, polypharmacy, referrals, and adverse drug events: are we doing things well?. British Journal of General Practice, 2012, 62, e821-e826.	0.7	163
41	Multimorbidity Patterns in Primary Care: Interactions among Chronic Diseases Using Factor Analysis. PLoS ONE, 2012, 7, e32190.	1.1	203
42	Underreporting of recognized adverse drug reactions by primary care physicians: an exploratory study. Pharmacoepidemiology and Drug Safety, 2011, 20, 1287-1294.	0.9	36
43	Urgencia en Atención Primaria: cuadros distónicos secundarios a la toma de neurolépticos. Semergen, 2009, 35, 357-358.	0.2	0